Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FHTX NASDAQ:OTLK NASDAQ:VERV NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$4.99-3.9%$5.41$2.94▼$10.25$293.39M3.0582,826 shs99,434 shsOTLKOncobiologics$1.05+1.0%$1.87$0.79▼$6.98$46.20M0.498.11 million shs3.47 million shsVERVVerve Therapeutics$11.13$11.13$2.86▼$11.40$992.13M2.233.94 million shsN/AXERSXeris Biopharma$7.36-1.7%$6.54$2.69▼$8.03$1.21B0.131.83 million shs1.49 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics-3.85%-13.22%+0.20%+4.18%-48.66%OTLKOncobiologics+0.96%+11.03%-55.13%-37.87%-83.77%VERVVerve Therapeutics0.00%0.00%0.00%-2.20%+102.36%XERSXeris Biopharma-1.74%-5.28%-4.17%+62.11%+155.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$4.99-3.9%$5.41$2.94▼$10.25$293.39M3.0582,826 shs99,434 shsOTLKOncobiologics$1.05+1.0%$1.87$0.79▼$6.98$46.20M0.498.11 million shs3.47 million shsVERVVerve Therapeutics$11.13$11.13$2.86▼$11.40$992.13M2.233.94 million shsN/AXERSXeris Biopharma$7.36-1.7%$6.54$2.69▼$8.03$1.21B0.131.83 million shs1.49 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics-3.85%-13.22%+0.20%+4.18%-48.66%OTLKOncobiologics+0.96%+11.03%-55.13%-37.87%-83.77%VERVVerve Therapeutics0.00%0.00%0.00%-2.20%+102.36%XERSXeris Biopharma-1.74%-5.28%-4.17%+62.11%+155.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFHTXFoghorn Therapeutics 3.17Buy$10.67113.76% UpsideOTLKOncobiologics 2.33Hold$9.60814.29% UpsideVERVVerve Therapeutics 2.33Hold$14.5730.92% UpsideXERSXeris Biopharma 2.83Moderate Buy$7.08-3.76% DownsideCurrent Analyst Ratings BreakdownLatest OTLK, FHTX, VERV, and XERS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025OTLKOncobiologicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/28/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.008/28/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral8/27/2025OTLKOncobiologicsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/19/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.008/15/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.008/12/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.006/27/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.506/26/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/18/2025VERVVerve TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$28.00 ➝ $11.006/18/2025VERVVerve TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFHTXFoghorn Therapeutics$22.60M12.48N/AN/A($0.82) per share-6.09OTLKOncobiologicsN/AN/AN/AN/A($3.09) per shareN/AVERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91XERSXeris Biopharma$246.03M4.83N/AN/A($0.20) per share-36.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFHTXFoghorn Therapeutics-$86.62M-$1.19N/AN/AN/A-311.90%N/A-28.00%11/3/2025 (Estimated)OTLKOncobiologics-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%N/AVERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/AXERSXeris Biopharma-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)Latest OTLK, FHTX, VERV, and XERS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025OTLKOncobiologics-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million8/7/2025Q2 2025XERSXeris Biopharma-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 million8/5/2025Q2 2025FHTXFoghorn Therapeutics-$0.31-$0.28+$0.03-$0.28$7.62 million$7.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFHTXFoghorn TherapeuticsN/A2.622.62OTLKOncobiologicsN/A0.670.54VERVVerve TherapeuticsN/A9.849.84XERSXeris BiopharmaN/A1.951.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFHTXFoghorn Therapeutics61.55%OTLKOncobiologics11.20%VERVVerve Therapeutics97.11%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipFHTXFoghorn Therapeutics7.58%OTLKOncobiologics4.80%VERVVerve Therapeutics19.30%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFHTXFoghorn Therapeutics12056.53 million52.25 millionOptionableOTLKOncobiologics2044.42 million42.29 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableXERSXeris Biopharma290161.48 million154.12 millionOptionableOTLK, FHTX, VERV, and XERS HeadlinesRecent News About These CompaniesAQR Capital Management LLC Has $5.20 Million Stake in Xeris Biopharma Holdings, Inc. $XERSSeptember 15 at 3:18 AM | marketbeat.comInsider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,500 Shares of StockSeptember 14 at 5:32 PM | marketbeat.comJacobs Levy Equity Management Inc. Acquires Shares of 255,560 Xeris Biopharma Holdings, Inc. $XERSSeptember 14 at 3:26 AM | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $7.08 Average PT from BrokeragesSeptember 14 at 2:21 AM | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Director Sells $119,660.00 in StockSeptember 13 at 6:54 AM | insidertrades.comFred Alger Management LLC Buys New Stake in Xeris Biopharma Holdings, Inc. $XERSSeptember 13 at 4:07 AM | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 12, 2025 | marketbeat.comWhat Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Significant Decline in Short InterestSeptember 9, 2025 | americanbankingnews.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest Down 26.7% in AugustSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $9.78 Million Stock Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 8, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Downgraded by Wall Street Zen to BuySeptember 8, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 7, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Stock Holdings Raised by Graham Capital Management L.P.September 7, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Rating Lowered by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comBosun Asset Management LLC Acquires New Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 6, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High - Time to Buy?September 5, 2025 | marketbeat.comXeris In Recorlev-Fuelled Growth: Why I Choose To BuySeptember 5, 2025 | seekingalpha.comPDT Partners LLC Buys New Shares in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comIeq Capital LLC Boosts Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comQuarry LP Makes New $388,000 Investment in Xeris Biopharma Holdings, Inc. $XERSSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLK, FHTX, VERV, and XERS Company DescriptionsFoghorn Therapeutics NASDAQ:FHTX$4.99 -0.20 (-3.85%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$4.99 0.00 (0.00%) As of 09/15/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Oncobiologics NASDAQ:OTLK$1.05 +0.01 (+0.96%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.06 +0.01 (+1.43%) As of 09/15/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Verve Therapeutics NASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Xeris Biopharma NASDAQ:XERS$7.36 -0.13 (-1.74%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$7.25 -0.11 (-1.49%) As of 09/15/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
